• Introduction
  • R&D Vision
  • Key Achievements
  • Pipeline
  • Partnership




NO. 1 API laboratory in Korea
Daewoong Bio Laboratory is recognized for its excellence, domestically and internationally, as reflected in our high quality products.

Daewoong Bio Laboratory proudly works as a superior laboratory in South Korea providing many outstanding advantages to our clients. Our technical skills allows us to produce high-purity products from natural sources, extra high-purity through highly efficient refining techniques, and provides opportunities to challenge patents by changing crystal forms and polymorph.

Our performance shows are strength. Daewoong Bio commercialized antibiotics such as cefuroxime axetil and cefodizime sodium, and was the first to do so in South Korea with patented manufacturing techniques. Daewoong Bio has commercialized ceftriaxone sodium, an injection produced through our new process.

Furthermore, Daewoong Bio has successfully industrially commercialized generics for gastric ulcers such as lansoprazole and rabeprazole, and antifungals, such as fluconazole, as reflected in the excellent effect on sales.

Daewoong Bio Laboratory are industrialized Coenzyme Q10 for the second time in the world, and the first in South Korea. Coenzyme Q10 is in all of our cells and blood and is essential for metabolism while having excellent antioxidizing properties. It is used in various medicines and health functional foods worldwide.

Daewoong Bio produces the highest quality Ursodeoxycholic acid (UDCA) through the implementation our continuous research. UDCA is the main ingredient for “Ursa”, a hugely popular product in South Korea. Daewoong Bio sells up to 55 million USD of Ursa per year.

In addition, Daewoong Bio has developed the manufacturing process for meropenem, a carbapenem antibiotic. Carbapenems are antibiotics with broad spectrum antibacterial activity cover both Gram-positive and Gram-negative bacteria and anaerobes. Meropenem has overcome the noted disadvantages of imipenem as imipenem hydrolyses in the kidneys inducing negative side effects on central nervous system.

In August 2011, Daewoong Pharmaceuticals launched the contrast medium Neobist (Iopromide) produced by Daewoong Bio. Daewoong Bio received a patent for our original manufacturing process combining extra high-purity and efficiency enabling Daewoong Bio’s Iopromide to be a much more stable Iopromide compared to others due to the lowered levels of impurities.